ATE285761T1 - Verwendung von inhibitoren der retinsäurewirkung zur wundheilung - Google Patents

Verwendung von inhibitoren der retinsäurewirkung zur wundheilung

Info

Publication number
ATE285761T1
ATE285761T1 AT97919115T AT97919115T ATE285761T1 AT E285761 T1 ATE285761 T1 AT E285761T1 AT 97919115 T AT97919115 T AT 97919115T AT 97919115 T AT97919115 T AT 97919115T AT E285761 T1 ATE285761 T1 AT E285761T1
Authority
AT
Austria
Prior art keywords
retin
inhibitors
wound healing
acid action
action
Prior art date
Application number
AT97919115T
Other languages
English (en)
Inventor
Michel Demarchez
Patricia Rossio
Andre Jomard
Original Assignee
Galderma Rech Dermatologique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Rech Dermatologique filed Critical Galderma Rech Dermatologique
Application granted granted Critical
Publication of ATE285761T1 publication Critical patent/ATE285761T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Cosmetics (AREA)
  • Cultivation Receptacles Or Flower-Pots, Or Pots For Seedlings (AREA)
AT97919115T 1996-09-20 1997-09-17 Verwendung von inhibitoren der retinsäurewirkung zur wundheilung ATE285761T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9611511A FR2753627B1 (fr) 1996-09-20 1996-09-20 Utilisation des inhibiteurs de l'activite de l'acide retinoique pour favoriser la cicatrisation
PCT/FR1997/001641 WO1998011886A1 (fr) 1996-09-20 1997-09-17 Utilisation des inhibiteurs de l'activite de l'acide retinoique pour favoriser la cicatrisation

Publications (1)

Publication Number Publication Date
ATE285761T1 true ATE285761T1 (de) 2005-01-15

Family

ID=9495934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97919115T ATE285761T1 (de) 1996-09-20 1997-09-17 Verwendung von inhibitoren der retinsäurewirkung zur wundheilung

Country Status (14)

Country Link
US (1) US5973007A (de)
EP (1) EP0874626B1 (de)
JP (1) JPH11500464A (de)
AR (1) AR008638A1 (de)
AT (1) ATE285761T1 (de)
AU (1) AU707390B2 (de)
BR (1) BR9709154A (de)
CA (1) CA2236309A1 (de)
DE (1) DE69732092D1 (de)
FR (1) FR2753627B1 (de)
MX (1) MX9803995A (de)
NZ (1) NZ330401A (de)
WO (1) WO1998011886A1 (de)
ZA (1) ZA978400B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436993B1 (en) * 1999-07-13 2002-08-20 The Salk Institute For Biological Studies Use of RAR antagonists as modulators of hormone mediated processes
AU2001290816A1 (en) 2000-09-13 2002-03-26 Bristol-Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
JP4473491B2 (ja) * 2002-05-28 2010-06-02 株式会社資生堂 毛穴縮小剤
US7105566B2 (en) * 2002-10-22 2006-09-12 Allergan, Inc. Methods of treatment during vascular procedures
FR2847167A1 (fr) * 2002-11-15 2004-05-21 Galderma Res & Dev UTILISATION D'UN ANTAGONISTE DES RECEPTEURS RARs POUR POTENTIALISER L'ACTION DU TGFb
AU2003302070A1 (en) * 2002-11-15 2004-06-15 Galderma Research And Development, S.N.C. USE OF AN RAR RECEPTOR ANTAGONIST FOR POTENTIATING THE ACTION OF TGFBeta
EP1748784A4 (de) * 2004-05-26 2008-02-13 Cedars Sinai Medical Center Induktion der angeborenen immunität mittels vitamin d3 und analoga
US20070049579A1 (en) * 2005-03-04 2007-03-01 Ryozo Nagai Medicament having neovascularization promoting action
EP1764411B1 (de) 2005-07-26 2013-10-02 Kao Corporation Alkalische Xylanase
US20080027031A1 (en) * 2006-03-08 2008-01-31 Kinemed, Inc. Retinoids and Related Compounds for the Treatment of Neuroinflammatory Conditions, Diseases and Disorders
FR2910321B1 (fr) 2006-12-21 2009-07-10 Galderma Res & Dev S N C Snc Gel creme comprenant au moins un retinoide et du peroxyde de benzole
FR2910320B1 (fr) 2006-12-21 2009-02-13 Galderma Res & Dev S N C Snc Emulsion comprenant au moins un retinoide et du peroxyde de benzole
FR2931661B1 (fr) 2008-05-30 2010-07-30 Galderma Res & Dev Nouvelles compositions depigmentantes sous forme d'une composition anhydre sans vaseline et sans elastomere comprenant un derive phenolique solubilise et un retinoide.
JP7457642B2 (ja) 2017-04-03 2024-03-28 ビオンテック ユーエス インコーポレイテッド タンパク質抗原およびその使用
US11793867B2 (en) 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
WO2019246286A1 (en) 2018-06-19 2019-12-26 Neon Therapeutics, Inc. Neoantigens and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ237003A (en) * 1990-02-12 1992-12-23 Squibb & Sons Inc A bandage comprising a retinoid in or on the skin contacting surface
FR2663850B1 (fr) * 1990-07-02 1994-01-14 Gird Galderma Composition pharmaceutique ou cosmetique contenant en association un retinouide et un sterol.
CA2093577C (en) * 1992-05-07 2006-01-03 Michael Klaus Alkyl or alkoxy substituted s-heterocyclic retinoids
ES2102195T3 (es) * 1992-12-28 1997-07-16 Eisai Co Ltd Derivados heterociclicos de acido carbonico que se fijan en receptores de retinoides.
FR2713640B1 (fr) * 1993-12-15 1996-01-05 Cird Galderma Nouveaux composés aromatiques polycycliques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
CA2138000A1 (en) * 1994-01-03 1995-07-04 John E. Starrett, Jr. Retinoid-like compounds
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
FR2735371B1 (fr) * 1995-06-19 1997-07-18 Cird Galderma Procede pour identifier des composes antagonistes des recepteurs rars
US5808124A (en) * 1996-06-21 1998-09-15 Allergan O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity

Also Published As

Publication number Publication date
FR2753627B1 (fr) 2003-02-21
FR2753627A1 (fr) 1998-03-27
CA2236309A1 (fr) 1998-03-26
AU4306197A (en) 1998-04-14
US5973007A (en) 1999-10-26
BR9709154A (pt) 1999-08-03
AU707390B2 (en) 1999-07-08
JPH11500464A (ja) 1999-01-12
DE69732092D1 (de) 2005-02-03
EP0874626B1 (de) 2004-12-29
NZ330401A (en) 1999-05-28
MX9803995A (es) 1998-09-30
WO1998011886A1 (fr) 1998-03-26
ZA978400B (en) 1998-03-26
AR008638A1 (es) 2000-02-09
EP0874626A1 (de) 1998-11-04

Similar Documents

Publication Publication Date Title
ATE371457T1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
DE69732092D1 (de) Verwendung von inhibitoren der retinsäurewirkung zur wundheilung
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
DE69600012D1 (de) Verwendung von Salicylsäure-Derivativen zur Hautbleichung
DE69827126D1 (de) Verwendung von hypothalamus-hemmfaktor zur behandlung von ischämischen herzstörungen
DE69528011D1 (de) Verfahren zur Pflege der Nägel
DE59611411D1 (de) Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz
DE69903655D1 (de) Verwendung von menthyl-2-pyrrolidon-5-carboxylat zur insektenabwehr
ATE219081T1 (de) Azabicyclishe carbaniumsaureester zur therapeutsichen verwendung
DE69427716D1 (de) Klebeverband zur Blutstillung
DE69634951D1 (de) Topische verwendung von betulinsäure zur behandlung bösartiger melanome
ATE259640T1 (de) Verwendung von matrix-metalloproteinase inhibitoren zur förderung der wundheilung
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE69531048D1 (de) Verwendung von steroidsulphatase-hemmern
DE59707519D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
EE03745B1 (et) Asendatud 4-bifenüül-4-hüdroksübutaanhappe derivaadid metalloproteaasimaatriksi inhibiitoritena
DE69635977D1 (de) Verfahren zur Bestimmung der therapeutischen Wirkung von Metalloproteinase-Verbindungen, neue Inhibitor-Verbindungen und deren therapeutische Verwendung
ATE233542T1 (de) Verwendung von inhibitoren der retinosäureaktivität zur behandlung empfindlicher haut und/oder durch uv strahlung bewirkter akuter schädigungen
DE69621447D1 (de) Verwendung von nitroflavonoide zur behandlung von angstzuständen
DE60026644D1 (de) Verwendung von Ferulasäure zur Behandlung von Bluthochdruck
DE59705697D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis
DE59712000D1 (de) Herstellung von Carbonsäurefluoriden
ATE245424T1 (de) Verwendung von hyaluronsäure zur zellmobilisierung
DE69834262D1 (de) Neue pharnazeutische verwendung von c-c chemokin produktionsinhibitoren
ATE433323T1 (de) Verwendung von erythropoietin zur behandlung von primärer hämochromatosen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties